One Drop App With an Activity Tracker for Adults With Type 1 Diabetes: Randomized Controlled Trial.
activity tracker
coaching
diabetes
digital therapy
glucometer
mobile app
type 1 diabetes
Journal
JMIR mHealth and uHealth
ISSN: 2291-5222
Titre abrégé: JMIR Mhealth Uhealth
Pays: Canada
ID NLM: 101624439
Informations de publication
Date de publication:
17 09 2020
17 09 2020
Historique:
received:
20
10
2019
accepted:
13
06
2020
revised:
24
01
2020
pubmed:
17
6
2020
medline:
16
3
2021
entrez:
17
6
2020
Statut:
epublish
Résumé
In 2017, mobile app support for managing diabetes was available to 64% of the global population of adults with diabetes. One Drop's digital therapeutics solution includes an evidence-based mobile app with global reach, a Bluetooth-connected glucometer, and in-app coaching from Certified Diabetes Educators. Among people with type 1 diabetes and an estimated hemoglobin A We conducted a pragmatic, remotely administered randomized controlled trial to evaluate One Drop with a new-to-market activity tracker against One Drop only on the 3-month hemoglobin A Social media advertisements and online newsletters were used to recruit adults (≥18 years old) diagnosed (≥1 year) with T1D, naïve to One Drop's full solution and the activity tracker, with a laboratory hemoglobin A The enrolled sample (N=95) had a mean age of 41 (SD 11) years, was 73% female, 88% White, diagnosed for a mean of 20 (SD 11) years, and had a mean hemoglobin A Participants exposed to One Drop and the activity tracker for the 3-month study period had a significantly lower 3-month hemoglobin A ClinicalTrials.gov NCT03459573; https://clinicaltrials.gov/ct2/show/NCT03459573.
Sections du résumé
BACKGROUND
In 2017, mobile app support for managing diabetes was available to 64% of the global population of adults with diabetes. One Drop's digital therapeutics solution includes an evidence-based mobile app with global reach, a Bluetooth-connected glucometer, and in-app coaching from Certified Diabetes Educators. Among people with type 1 diabetes and an estimated hemoglobin A
OBJECTIVE
We conducted a pragmatic, remotely administered randomized controlled trial to evaluate One Drop with a new-to-market activity tracker against One Drop only on the 3-month hemoglobin A
METHODS
Social media advertisements and online newsletters were used to recruit adults (≥18 years old) diagnosed (≥1 year) with T1D, naïve to One Drop's full solution and the activity tracker, with a laboratory hemoglobin A
RESULTS
The enrolled sample (N=95) had a mean age of 41 (SD 11) years, was 73% female, 88% White, diagnosed for a mean of 20 (SD 11) years, and had a mean hemoglobin A
CONCLUSIONS
Participants exposed to One Drop and the activity tracker for the 3-month study period had a significantly lower 3-month hemoglobin A
TRIAL REGISTRATION
ClinicalTrials.gov NCT03459573; https://clinicaltrials.gov/ct2/show/NCT03459573.
Identifiants
pubmed: 32540842
pii: v8i9e16745
doi: 10.2196/16745
pmc: PMC7530691
doi:
Substances chimiques
Glycated Hemoglobin A
0
Banques de données
ClinicalTrials.gov
['NCT03459573']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16745Informations de copyright
©Chandra Y Osborn, Ashley Hirsch, Lindsay E Sears, Mark Heyman, Jennifer Raymond, Brian Huddleston, Jeff Dachis. Originally published in JMIR mHealth and uHealth (http://mhealth.jmir.org), 17.09.2020.
Références
Arch Intern Med. 2000 Feb 14;160(3):301-8
pubmed: 10668831
Perspect Clin Res. 2016 Jul-Sep;7(3):144-6
pubmed: 27453832
JMIR Mhealth Uhealth. 2016 Jan 20;4(1):e5
pubmed: 26792225
J Diabetes Sci Technol. 2015 Dec 20;10(1):35-41
pubmed: 26685994
JMIR Mhealth Uhealth. 2017 Nov 29;5(11):e179
pubmed: 29187344
Pediatr Diabetes. 2018 Feb 21;:
pubmed: 29464831
Diabetes Care. 2003 Apr;26(4):1079-87
pubmed: 12663577
Diabetes Care. 2018 May;41(5):917-928
pubmed: 29567642
Public Health Nurs. 2012 May-Jun;29(3):232-40
pubmed: 22512424
PLoS One. 2017 Jan 25;12(1):e0170219
pubmed: 28121997
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Diabetes Care. 2016 Dec;39(12):2165-2173
pubmed: 27456837
Epidemiology. 2013 Sep;24(5):773-4
pubmed: 23903880
Diabetes Care. 2005 May;28(5):1231-9
pubmed: 15855600
Am J Health Behav. 2011 Jan-Feb;35(1):118-28
pubmed: 20950164
Int J Behav Nutr Phys Act. 2015 Jan 24;12:4
pubmed: 25616598
Diabetes Res Clin Pract. 2011 Oct;94(1):77-83
pubmed: 21737172
Diabetes Care. 2019 Jan;42(Suppl 1):S61-S70
pubmed: 30559232
BMC Med. 2018 Apr 3;16(1):49
pubmed: 29615035
Diabetes Care. 2014;37(5):1246-53
pubmed: 24598245
JAMA. 2014 Jul 2;312(1):85-6
pubmed: 25058221
Diabetes Care. 2019 Jan;42(Suppl 1):S46-S60
pubmed: 30559231
BMC Med Res Methodol. 2014 Apr 09;14:49
pubmed: 24712304
N Engl J Med. 2017 Oct 5;377(14):1391-1398
pubmed: 28976864
Am J Med. 2017 Jul;130(7):867-871
pubmed: 28392186
Diabetes Care. 2014;37(1):9-16
pubmed: 24356592
Ann Behav Med. 2017 Feb;51(1):79-93
pubmed: 27565168
Contemp Clin Trials Commun. 2018 May 06;10:161-168
pubmed: 30035241
PLoS One. 2018 Jan 2;13(1):e0189298
pubmed: 29293532
BMJ. 2010 Mar 23;340:c869
pubmed: 20332511
JMIR Diabetes. 2017 Aug 24;2(2):e21
pubmed: 30291059
Diabetes Care. 2018 Aug;41(8):1681-1688
pubmed: 29898901
Diabetes Ther. 2017 Feb;8(1):75-83
pubmed: 27995595
Diabetes Technol Ther. 2018 Jun;20(S2):S216-S223
pubmed: 29873517